Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohan Ameratunga

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Journal of Clinical Immunology|August 13, 2014
Identification of germinal centres in the lymph node of a patient with hyperimmunoglobulin M syndrome associated with congenital rubellaRohan Ameratunga, Chun-Jen J Chen, Wikke Koopmans, et al.
American Heart Journal|January 31, 2006
Effects of exercise training on 5 inflammatory markers associated with cardiovascular riskChristopher J K Hammett, Harry Prapavessis, J Chris Baldi, et al.
Journal of the American College of Cardiology|December 21, 2004
Effect of six months' exercise training on C-reactive protein levels in healthy elderly subjectsChristopher J K Hammett, Helen C Oxenham, J Chris Baldi, et al.
Preventive Cardiology|March 31, 2007
Variation in blood levels of inflammatory markers related and unrelated to smoking cessation in womenChristopher J K Hammett, Harry Prapavessis, J Chris Baldi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2023
The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like DisordersRohan Ameratunga, Emily S J Edwards, Klaus Lehnert, et al.
Clinical and Experimental Immunology|August 11, 2023
Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19Rohan Ameratunga, Emily Mears, Euphemia Leung, et al.
Journal of Clinical Immunology|January 3, 2022
First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity ReactionRohan Ameratunga, See-Tarn Woon, Mary N Sheppard, et al.
Expert Review of Clinical Immunology|April 1, 2021
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infectionRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
Clinical & Translational Immunology|November 9, 2017
Epistatic interactions between mutations of TACI (<i>TNFRSF13B</i>) and <i>TCF3</i> result in a severe primary immunodeficiency disorder and systemic lupus erythematosusRohan Ameratunga, Wikke Koopmans, See-Tarn Woon, et al.
The New Zealand Medical Journal|May 22, 2020
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infectionRohan Ameratunga, Klaus Lehnert, Euphemia Leung, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Journal of Clinical Immunology|August 13, 2014
Identification of germinal centres in the lymph node of a patient with hyperimmunoglobulin M syndrome associated with congenital rubellaRohan Ameratunga, Chun-Jen J Chen, Wikke Koopmans, et al.
American Heart Journal|January 31, 2006
Effects of exercise training on 5 inflammatory markers associated with cardiovascular riskChristopher J K Hammett, Harry Prapavessis, J Chris Baldi, et al.
Journal of the American College of Cardiology|December 21, 2004
Effect of six months' exercise training on C-reactive protein levels in healthy elderly subjectsChristopher J K Hammett, Helen C Oxenham, J Chris Baldi, et al.
Preventive Cardiology|March 31, 2007
Variation in blood levels of inflammatory markers related and unrelated to smoking cessation in womenChristopher J K Hammett, Harry Prapavessis, J Chris Baldi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2023
The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like DisordersRohan Ameratunga, Emily S J Edwards, Klaus Lehnert, et al.
Clinical and Experimental Immunology|August 11, 2023
Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19Rohan Ameratunga, Emily Mears, Euphemia Leung, et al.
Journal of Clinical Immunology|January 3, 2022
First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity ReactionRohan Ameratunga, See-Tarn Woon, Mary N Sheppard, et al.
Expert Review of Clinical Immunology|April 1, 2021
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infectionRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
Clinical & Translational Immunology|November 9, 2017
Epistatic interactions between mutations of TACI (<i>TNFRSF13B</i>) and <i>TCF3</i> result in a severe primary immunodeficiency disorder and systemic lupus erythematosusRohan Ameratunga, Wikke Koopmans, See-Tarn Woon, et al.
The New Zealand Medical Journal|May 22, 2020
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infectionRohan Ameratunga, Klaus Lehnert, Euphemia Leung, et al.
Pageof 10